ES2168322T3 - Sustancias acondicionadas solubles en agua. - Google Patents

Sustancias acondicionadas solubles en agua.

Info

Publication number
ES2168322T3
ES2168322T3 ES95111178T ES95111178T ES2168322T3 ES 2168322 T3 ES2168322 T3 ES 2168322T3 ES 95111178 T ES95111178 T ES 95111178T ES 95111178 T ES95111178 T ES 95111178T ES 2168322 T3 ES2168322 T3 ES 2168322T3
Authority
ES
Spain
Prior art keywords
water
soluble conditioning
conditioning substances
substances
stable
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES95111178T
Other languages
English (en)
Spanish (es)
Inventor
Katarina Ulla Bystrom
Edib Jakupovic
Jan William Trofast
Eva Ann-Christin Trofast
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
AstraZeneca AB
Original Assignee
AstraZeneca AB
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=20382434&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ES2168322(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by AstraZeneca AB filed Critical AstraZeneca AB
Application granted granted Critical
Publication of ES2168322T3 publication Critical patent/ES2168322T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Otolaryngology (AREA)
  • Medicinal Preparation (AREA)
  • Food Preservation Except Freezing, Refrigeration, And Drying (AREA)
  • Compounds Of Unknown Constitution (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Detergent Compositions (AREA)
  • Paper (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Solid-Sorbent Or Filter-Aiding Compositions (AREA)
  • General Preparation And Processing Of Foods (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Treating Waste Gases (AREA)
  • Cosmetics (AREA)
  • Cephalosporin Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Silver Salt Photography Or Processing Solution Therefor (AREA)
ES95111178T 1991-04-11 1992-03-24 Sustancias acondicionadas solubles en agua. Expired - Lifetime ES2168322T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
SE9101090A SE9101090D0 (sv) 1991-04-11 1991-04-11 Process for conditioning of water-soluble substances

Publications (1)

Publication Number Publication Date
ES2168322T3 true ES2168322T3 (es) 2002-06-16

Family

ID=20382434

Family Applications (2)

Application Number Title Priority Date Filing Date
ES95111178T Expired - Lifetime ES2168322T3 (es) 1991-04-11 1992-03-24 Sustancias acondicionadas solubles en agua.
ES92907877T Expired - Lifetime ES2086733T3 (es) 1991-04-11 1992-03-24 Procedimiento para acondicionar sustancias solubles en agua.

Family Applications After (1)

Application Number Title Priority Date Filing Date
ES92907877T Expired - Lifetime ES2086733T3 (es) 1991-04-11 1992-03-24 Procedimiento para acondicionar sustancias solubles en agua.

Country Status (28)

Country Link
US (1) US5562923A (enExample)
EP (3) EP0680752B1 (enExample)
JP (2) JP3400999B2 (enExample)
KR (1) KR100216384B1 (enExample)
AT (2) ATE208613T1 (enExample)
AU (1) AU662519B2 (enExample)
BG (1) BG61474B1 (enExample)
CA (1) CA2106975C (enExample)
CZ (1) CZ286936B6 (enExample)
DE (2) DE69232207T2 (enExample)
DK (2) DK0580648T3 (enExample)
EE (1) EE02970B1 (enExample)
ES (2) ES2168322T3 (enExample)
FI (1) FI105388B (enExample)
GR (1) GR3020602T3 (enExample)
HK (1) HK52497A (enExample)
HU (1) HU211116B (enExample)
IE (1) IE921144A1 (enExample)
IS (1) IS3834A (enExample)
NO (1) NO311867B1 (enExample)
PL (1) PL168232B1 (enExample)
PT (1) PT680752E (enExample)
RO (1) RO115779B1 (enExample)
RU (1) RU2112507C1 (enExample)
SE (1) SE9101090D0 (enExample)
SG (1) SG43180A1 (enExample)
SK (1) SK280310B6 (enExample)
WO (1) WO1992018110A1 (enExample)

Families Citing this family (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE9302777D0 (sv) * 1993-08-27 1993-08-27 Astra Ab Process for conditioning substances
US5874063A (en) * 1991-04-11 1999-02-23 Astra Aktiebolag Pharmaceutical formulation
US5980949A (en) * 1994-10-03 1999-11-09 Astra Aktiebolag Formulation for inhalation
US5983956A (en) * 1994-10-03 1999-11-16 Astra Aktiebolag Formulation for inhalation
CA2213700C (en) 1995-02-28 2002-04-02 Hoechst Marion Roussel, Inc. Pharmaceutical composition for piperidinoalkanol compounds
US5654007A (en) * 1995-06-07 1997-08-05 Inhale Therapeutic Systems Methods and system for processing dispersible fine powders
GB9526392D0 (en) * 1995-12-22 1996-02-21 Glaxo Group Ltd Medicaments
SE9700135D0 (sv) 1997-01-20 1997-01-20 Astra Ab New formulation
SE9700133D0 (sv) * 1997-01-20 1997-01-20 Astra Ab New formulation
US6503537B2 (en) 1997-03-20 2003-01-07 Schering Corporation Preparation of powder agglomerates
ATE284677T1 (de) * 1997-03-20 2005-01-15 Schering Corp Herstellung von pulveragglomeraten
US6495167B2 (en) 1997-03-20 2002-12-17 Schering Corporation Preparation of powder agglomerates
PT998272E (pt) * 1997-08-26 2003-09-30 Aventis Pharma Inc Composicao farmaceutica para combinacao do descongestionante piperidinoalcanol
US20060165606A1 (en) 1997-09-29 2006-07-27 Nektar Therapeutics Pulmonary delivery particles comprising water insoluble or crystalline active agents
DE69814428T2 (de) * 1997-09-29 2004-05-13 Nektar Therapeutics, San Carlos In verneblern verwendbare, stabilisierte zubereitungen
FI105074B (fi) * 1997-12-31 2000-06-15 Leiras Oy Farmaseuttisen formulaation valmistusmenetelmä
US6287693B1 (en) 1998-02-25 2001-09-11 John Claude Savoir Stable shaped particles of crystalline organic compounds
SE9804000D0 (sv) 1998-11-23 1998-11-23 Astra Ab New composition of matter
GB9826286D0 (en) * 1998-12-01 1999-01-20 Rhone Poulence Rorer Limited Process
GB9826284D0 (en) * 1998-12-01 1999-01-20 Rhone Poulence Rorer Limited Process
US8722668B2 (en) * 1998-12-23 2014-05-13 Daryl W. Hochman Methods and compositions for the treatment of neuropathic pain and neuropsychiatric disorders
US6623760B1 (en) 1999-01-28 2003-09-23 Schering Corporation Method of preparing particles for agglomeration
AR022695A1 (es) * 1999-01-28 2002-09-04 Schering Corp PORTADOR SoLIDO PARTICULADO Y MÉTODO PARA PROVEER CONTROL DE LA PARTICULADA PARA LA DISTRIBUCIoN DE TAMANO DE PARTíCULAS Y DE CONTENIDO AMORFO CONVERTIBLE DURANTE SU PREPARACION
US7871598B1 (en) 2000-05-10 2011-01-18 Novartis Ag Stable metal ion-lipid powdered pharmaceutical compositions for drug delivery and methods of use
US7309707B2 (en) 2002-03-20 2007-12-18 Boehringer Ingelheim Pharma Gmbh & Co. Kg Crystalline micronisate, process for the manufacture thereof and use thereof for the preparation of a medicament
US7244415B2 (en) 2002-03-28 2007-07-17 Boehringer Ingelheim Pharma Gmbh & Co. Kg HFA suspension formulations of an anhydrate
US20040028746A1 (en) * 2002-08-06 2004-02-12 Sonke Svenson Crystalline drug particles prepared using a controlled precipitation (recrystallization) process
GB0228826D0 (en) * 2002-12-11 2003-01-15 Okpala Joseph Hair technology in creating particles with improved delivery capabilities
WO2004087102A2 (en) * 2003-03-26 2004-10-14 Teva Pharmaceutical Industries Ltd. A process for preparing a pharmaceutical active ingredient with high specific surface area
PL1844765T3 (pl) 2003-06-13 2015-06-30 Skendi Finance Ltd Formulacja estradiol-progesteron o spowolnionym uwalnianiu
GB0323684D0 (en) 2003-10-09 2003-11-12 Jagotec Ag Improvements in or relating to organic compounds
AU2004281270B2 (en) * 2003-10-17 2010-05-06 E.I. Dupont De Nemours And Company Adhesion of foil to thermoplastic polymers
BRPI0506610A (pt) 2004-02-03 2007-05-02 Chemagis Ltd montelucaste sódico amorfo, processo de preparação de montelucaste sódico amorfo, composição farmacêutica, método de tratamento utilizando a administração de montelucaste sódico amorfo, co-precipitado amorfo de montelucaste sódico e processo de preparação de co-precipitado amorfo de montelucaste sódico
DE102004048390A1 (de) 2004-10-01 2006-04-06 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue Pulverinhalativa auf Basis modifizierter Laktosemischungen als Hilfsstoff
DE102004048389A1 (de) 2004-10-01 2006-04-06 Boehringer Ingelheim Pharma Gmbh & Co. Kg Modifizierung von Oberflächen von Laktose als Hilfsstoff zur Verwendung für Pulverinhalativa
US20070286814A1 (en) * 2006-06-12 2007-12-13 Medispray Laboratories Pvt. Ltd. Stable aerosol pharmaceutical formulations
PT2234595E (pt) * 2007-12-13 2013-01-24 Novartis Ag Processo para redução da tendência de um sal de glicopirrónio para se agregar durante a armazenagem
RU2376079C1 (ru) * 2008-06-11 2009-12-20 Государственное образовательное учреждение высшего профессионального образования "Московский государственный университет инженерной экологии" Способ получения порошков микронизированных частиц
GB0918149D0 (en) 2009-10-16 2009-12-02 Jagotec Ag Improved medicinal aerosol formulation
US20110224229A1 (en) 2010-03-10 2011-09-15 Astrazeneca Ab Novel Crystalline Form
RU2013153466A (ru) 2011-06-29 2015-08-10 Астразенека Аб Кристаллическая форма производных индазолиламида для лечения опосредованных глюкокортикоидными рецепторами расстройств
SG11201507286QA (en) * 2013-03-15 2015-10-29 Pearl Therapeutics Inc Methods and systems for conditioning of particulate crystalline materials
WO2021219230A1 (en) 2020-04-30 2021-11-04 Paolo Fiorina Antiviral treatment

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3978192A (en) * 1971-09-23 1976-08-31 Sussman Martin V Method of drawing fibers using a microterraced drawing surface
US4405598A (en) * 1976-01-30 1983-09-20 Fisons, Limited Composition for treating asthma
KR890000664B1 (ko) * 1981-10-19 1989-03-22 바리 안소니 뉴우샘 미분된 베클로메타손 디프로피오네이트 일수화물의 제조방법
US4476130A (en) * 1982-09-09 1984-10-09 Riker Laboratories, Inc. 3-(1H-Tetrazol-5-yl)-4H-pyrimido[2,1-b]benzoxazol-4-one compounds exhibiting anti-allergic activity
JPH08186B2 (ja) * 1985-06-21 1996-01-10 ゲルゲリイ、ゲルハルト プロセス材料から反応生成物を製造する方法及びその装置
IT1204826B (it) * 1986-03-04 1989-03-10 Chiesi Farma Spa Composizioni farmaceutiche per inalazione
KR100229754B1 (ko) * 1989-11-24 1999-11-15 샬러 한스, 하우스 한스 루돌프 판크레아틴구형입자, 이의 제조방법 및 이를 함유하는 약제학적 조성물
US5145684A (en) * 1991-01-25 1992-09-08 Sterling Drug Inc. Surface modified drug nanoparticles

Also Published As

Publication number Publication date
EP0680752B1 (en) 2001-11-14
US5562923A (en) 1996-10-08
EP0580648A1 (en) 1994-02-02
FI934429A0 (fi) 1993-10-08
BG98147A (bg) 1994-12-02
CZ211693A3 (en) 1994-04-13
SK108893A3 (en) 1994-03-09
DE69210601T2 (de) 1996-10-02
CA2106975A1 (en) 1992-10-12
DK0680752T3 (da) 2002-02-25
HU9302870D0 (en) 1993-12-28
SE9101090D0 (sv) 1991-04-11
AU662519B2 (en) 1995-09-07
GR3020602T3 (en) 1996-10-31
HK52497A (en) 1997-05-02
DE69232207T2 (de) 2002-08-01
DE69232207D1 (de) 2001-12-20
CZ286936B6 (cs) 2000-08-16
EP0508969A1 (en) 1992-10-14
JP3400999B2 (ja) 2003-04-28
PT680752E (pt) 2002-05-31
PL168232B1 (pl) 1996-01-31
RU2112507C1 (ru) 1998-06-10
NO933575L (no) 1993-10-06
FI105388B (fi) 2000-08-15
EP0680752A2 (en) 1995-11-08
AU1534792A (en) 1992-11-17
CA2106975C (en) 2002-03-19
ATE208613T1 (de) 2001-11-15
EE02970B1 (et) 1997-04-15
EP0680752A3 (enExample) 1995-11-22
ATE137671T1 (de) 1996-05-15
WO1992018110A1 (en) 1992-10-29
IS3834A (is) 1992-10-12
IE921144A1 (en) 1992-10-21
FI934429L (fi) 1993-10-08
DE69210601D1 (de) 1996-06-13
SK280310B6 (sk) 1999-11-08
BG61474B1 (en) 1997-09-30
KR100216384B1 (ko) 1999-08-16
RO115779B1 (ro) 2000-06-30
HU211116B (en) 1995-10-30
ES2086733T3 (es) 1996-07-01
HUT65095A (en) 1994-04-28
NO933575D0 (no) 1993-10-06
DK0580648T3 (da) 1996-09-16
JPH06506454A (ja) 1994-07-21
NO311867B1 (no) 2002-02-11
JP2003155228A (ja) 2003-05-27
EP0580648B1 (en) 1996-05-08
SG43180A1 (en) 1997-10-17

Similar Documents

Publication Publication Date Title
ES2168322T3 (es) Sustancias acondicionadas solubles en agua.
DE3689252D1 (de) Arzneimittel gegen chronische Graft-versus-Host-Krankheiten sowie gegen Autoimmunerkrankungen, insbesondere systemischen Lupus erythematodes.
IT1211484B (it) Forma farmaceutica di dosaggio per somministrazione orale con erogazione controllata di un ingrediente attivo
NO306850B1 (no) Anvendelse av 5-halo-2-pyrimidinon-deoksyribose eller 5-halo-2-pyrimidinon for fremstilling av et medikament for behandling av leversykdom
MX9101175A (es) Composicion farmaceutica para administracion nasal
ES513357A0 (es) "un sistema terapeutico bajo la forma de un vendaje para administrar el medicamento".
IT1104643B (it) Sistema terapeutico in forma di cerotto o simile per la somministrazione di clonidina per via transdermica e procedimento per la sua preparazione
IT9020025A0 (it) Dispositivo per la somministrazione di sostanze medicamentose in polvere
IT7928301A0 (it) Forme galeniche di somministrazione di medicamenti per via orale,a liberazione programmata,e loro procedimenti di preparazione
IT8248730A0 (it) Perfezionamento negli inalatori a dosaggio per la somministrazione di preparati farmacologici
ES2157944T3 (es) Nucleos de pastillas de liberacion inmediata de medicamentos insolubles que poseen un recubrimiento de liberacion sostenida.
LV10953A (lv) Aizvietotie benzimidazoli to iegusanas panemiens pielietojums farmaceitiska kompozicija
KR930007441A (ko) 의약품
DE68903605D1 (de) Kautablette.
MX9100080A (es) Composiciones farmaceuticas y metodos para aliviar sintomas gastrointestinales inducidos por drogas antiinflamatorias no esteroidales
FI923308A0 (fi) Foerbaettrade preparat innehaollande dideoxpurinnukleosider foer oral administration.
DK616186A (da) Farmaceutisk praeparat med retarderet frigivelse af ibuprofen
ITMI921930A1 (it) Composizioni farmaceutiche per la somministrazione orale di diidropiridine in forma di bevanda
EP0438147A3 (en) Pharmaceutical compositions and dosage forms for the oral administration of calcitonin
MX9203615A (es) Composicion farmaceutica en forma de polvo para administracion nasal.
AU8014091A (en) Pharmaceutical compositions and methods for alleviating gastrointestinal distress symptoms induced by nonsteroidal anti-inflammatory drugs
MX9301189A (es) Forma de administracion farmaceutica, solida, finamente dividida, para administracion oral, disuelta o suspendida en un liquido farmaceuticamente aceptable y procedimiento para su preparacion.
DE68908414D1 (de) Pharmazeutische zusammensetzungen fuer die reizung eines immunostimulierenden effektes.
MX9205454A (es) Composicion farmaceutica para administracion oral al tracto gastrointestinal que comprende calcitonina
DE69026295D1 (de) Pharmazeutische Zusammensetzung gegen durch Vasokonstriktion hervorgerufene Krankheiten

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 680752

Country of ref document: ES